Portable electrochemical micro-workstation platform for simultaneous detection of multiple Alzheimer's disease biomarkers

Enhancing biosensing of trace tau protein in clinical samples via emergence macroscopic directed aggregation

Alzheimer's disease (AD) is an irreversible neurodegenerative disorder that poses a significant risk to human health and well-being. The high cost and invasiveness of neuroimaging and cerebrospinal fluid (CSF) analysis underscores the necessity for accessible early screening via blood samples. In this study, we developed an ultrasound-based strategy for emergent macroscopic that enhances the acoustic response enrichment of specific proteins by introducing functionalized microspheres. This customized macroscopic-directed aggregation method combines protein enrichment with specific fluorescent antibody recognition, enabling quantitative detection characterized by high sensitivity and specificity for tau proteins in clinical samples. In comparison with previously reported biosensing platforms, this strategy achieves indirectly driven clustering of tau proteins by integrating an acoustic resonant chamber, realizing facile and low-cost enrichment detection of protein without the need for amplification. Results demonstrate that this method exhibits a linear detection range from 1 pg/mL to 10 ng/mL, with a detection limit of 0.183 pg/mL. AD patients and healthy individuals were successfully distinguished with an accuracy of 90.9%. This ultrasonic biosensing strategy based on protein aggregation exhibits potential as a valuable tool for early screening of AD.

Biosensing systems for the detection of biomarkers of neurodegenerative diseases: A review

Neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and multiple sclerosis (MS) are pathologies associated with neuronal disorders and degradation. They are difficult to detect in their early stages, when it is crucial for appropriate treatment to be implemented. Currently, many biosensors are being developed to enable the determination of compounds characteristic of the aforementioned diseases. This review includes a de-scription of the structure of biosensors, as well as their applications in many areas of qualitative and quantitative analysis, with particular emphasis on diagnostics. The structures of biosensors that can potentially be used for the diagnosis of AD, PD and MS are discussed, as well as their characteristics, which depend on the technique used for the analysis and the type of recognition element capable of specifically binding a given biomarker. A description is also given of biosensors classified according to the type of sample used for quantitative determinations.

Brain-Computer Interface and Electrochemical Sensor Based on Boron-Nitrogen Co-Doped Graphene-Diamond Microelectrode for EEG and Dopamine Detection

The simultaneous detection of electroencephalography (EEG) signals and neurotransmitter levels plays an important role as biomarkers for the assessment and monitoring of emotions and cognition. This paper describes the development of boron and nitrogen codoped graphene-diamond (BNGrD) microelectrodes with a diameter of only 200 μm for sensing EEG signals and dopamine (DA) levels, which have been developed for the first time. The optimized BNGrD microelectrode responded sensitively to both EEG and DA signals, with a signal-to-noise ratio of 9 dB for spontaneous EEG signals and a limit of detection as low as 124 nM for DA. Furthermore, the BNGrD microelectrodes demonstrate excellent repeatability, reproducibility, and stability for the detection of EEG and dopamine. These results indicate that the BNGrD microelectrode creates suitable conditions for establishing a correlation between the EEG signals and neurotransmitters. A flexible printed circuit board with BNGrD microelectrodes for an eight-channel EEG headband, portable EEG collector, and light stimulation glasses are designed. The self-designed EEG collector adopts a split design strategy of digital and analog signal modules and uses miniaturized impedance-matched BNGrD microelectrodes, which effectively reduce the noise of the electrophysiological signals. The BNGrD microelectrode-based portable EEG/electrochemical analysis system detects EEG signals and DA levels in a noninvasive and minimally invasive manner and has application prospects in remote online diagnosis and treatment of patients with emotional and cognition-related diseases.

VG@nAu-based fluorescent biosensor for grading Alzheimer's disease by detecting P-tau181 protein in clinical samples

BACKGROUND

Alzheimer's disease (AD) is a neurodegenerative disorder with a very long duration, posing a serious threat to people's life and health. To date, no medicine that can cure or reverse the disease has been developed or reported, so early diagnosis and timely intervention are essential. The concentration of Phosphorylated tau181 (P-tau181) in blood has been approved by FDA as a standard for assisting clinical diagnosis of AD.

RESULTS

In this study, a fluorescence biosensor based on vertical graphene-modified nano-gold film (VG@nAu) was developed for the grading of AD diagnosis by detecting P-tau181 protein in the blood. The VG@nAu substrate that produces hundreds of times IR800 molecular compared with a glass substrate, which is prepared by sputtering nano-gold onto vertical graphene surface. The detection limit of this fluorescence biosensor for P-tau181 is 0.82 pg/mL. The sensor also shows excellent selectivity and stability. Moreover, we analyzed the levels of P-tau181 in 16 clinical samples divided into four groups (HC group, SCD group, MCI group, and AD group) and found significant differences in P-tau181 levels. The grouping result based on the detection results using this biosensor is consistent with the grouping results of the clinical doctors.

SIGNIFICANCE

This study achieves ultrasensitive detection of P-tau181 protein by constructing a fluorescent biosensor, which validates the feasibility of the VG@nAu-based fluorescence biosensor for the grading of AD diagnosis. This research provides a promising tool for ultrasensitive detecting biomarkers in clinical samples, indicating significant potential for its use in related diagnosing disease.

Using Machine Learning to Design a FeMOF Bidirectional Regulator for Electrochemiluminescence Sensing of Tau Protein

The single-luminophore-based ratiometric electrochemiluminescence (ECL) sensor coupling bidirectional regulator has become a research hotspot in the detection field because of its simplicity and accuracy. However, the limited bidirectional regulator hinders its further development. In this study, by leveraging the robust predictive capabilities of machine learning, we prepared an Fe-based metal-organic framework (FeMOF) as a bidirectional regulator for modulating the dual-emission ECL signals of a single luminophore for the first time. The proof of concept was demonstrated by applying FeMOF to the classical luminophore Ru(bpy)32+, and the results showed its ability to enhance the cathode ECL signal (Ecathode) and inhibit the anode ECL signal (Eanode). As an example, a ratiometric ECL sensor for Tau protein (Tau) detection utilizing the FeMOF/Ru(bpy)32+ system was developed. The incorporation of a bidirectional regulator in the ECL system effectively mitigated erratic fluctuations or minor discrepancies between the two signals and showed a stronger correlation and stability of Ecathode/Eanode than before regulation. As a result, the ECL sensor showed good analytical performance with a detection limit as low as 3.38 fg mL-1 (S/N = 3). Moreover, it was not only comparable in test results to the commercially available ELISA kit but also could well distinguish between normal and Alzheimer's disease (AD) patients (80% specificity and 90% sensitivity). Thus, the proposed strategy is promising to be extended to other ECL luminophores or MOFs, providing a new path for ratiometric ECL sensors.

Biomarkers in Alzheimer's disease

Alzheimer's disease (AD) is among the most common neurodegenerative disorders. AD is characterized by deposition of neurofibrillary tangles and amyloid plaques, leading to associated secondary pathologies, progressive neurodegeneration, and eventually death. Currently used diagnostics are largely image-based, lack accuracy and do not detect early disease, ie, prior to onset of symptoms, thus limiting treatment options and outcomes. Although biomarkers such as amyloid-β and tau protein in cerebrospinal fluid have gained much attention, these are generally limited to disease progression. Unfortunately, identification of biomarkers for early and accurate diagnosis remains a challenge. As such, body fluids such as sweat, serum, saliva, mucosa, tears, and urine are under investigation as alternative sources for biomarkers that can aid in early disease detection. This review focuses on biomarkers identified through proteomics in various biofluids and their potential for early and accurate diagnosis of AD.

Colorimetric detection of electrolyte ions in blood based on biphasic microdroplet extraction

BACKGROUND

Timely diagnosis and prevention of diseases require rapid and sensitive detection of biomarkers from blood samples without external interference. Abnormal electrolyte ion levels in the blood are closely linked to various physiological disorders, including hypertension. Therefore, accurate, interference-free, and precise measurement of electrolyte ion concentrations in the blood is particularly important.

RESULTS

In this work, a colorimetric sensor based on a biphasic microdroplet extraction is proposed for the detection of electrolyte ions in the blood. This sensor employs mini-pillar arrays to facilitate contact between adjacent blood microdroplets and organic microdroplets serving as sensing phases, with any color changes being monitored through a smartphone's colorimetric software. The sensor is highly resistant to interference and does not require pre-treatment of the blood samples. Remarkably, the sensor exhibits exceptional reliability and stability, allowing for rapid enrichment and detection of K+, Na+, and Cl- in the blood within 10 s (Cl-), 15 s (K+) and 40 s (Na+) respectively.

SIGNIFICANCE

The colorimetric sensor based on biphasic microdroplet extraction offers portability due to its compact size and ease of operation without the need for large instruments. Additionally, it is location-independent, making it a promising tool for real-time biomarker detection in body fluids such as blood.

Integrated phase separation in microliter droplets for ultratrace-enriching biomarker analysis

Ultratrace-enriching biomarker analysis is an effective method for achieving highly accurate and enhanced sensitive detection. In this study, we have developed an enrichment detection platform by combining a minipillar array with an aqueous two-phase system (ATPS) for ultratrace enriching biomarker analysis. After optimizing the enrichment conditions of ATPS, target miRNAs at ultratrace levels specifically accumulate in the DEX-rich phase, which significantly increases the target miRNA concentration-related fluorescence intensity. Compared to non-enriched miRNA in the single-phase PEG solution, the detection limit of ATPS-enriched miRNA had improved more than 200-fold. The ATPS-based enrichment detection strategy offers a novel and convenient approach for the simultaneous detection of biomarkers with ultratrace.

Ultrasound-enhanced catalytic hairpin assembly capable of ultrasensitive microRNA biosensing for the early screening of Alzheimer's disease

Catalytic hairpin assembly (CHA) is a promising enzyme-free, isothermal signal amplification strategy, but the relatively time-consuming strand replacement limits its application scenarios. Here, we developed an ultrasound-enhanced catalytic hairpin assembly (UECHA) biosensing platform for early screening of Alzheimer's disease by introducing a portable acoustic-drive platform with functionalized microspheres for effective biomarkers enrichment and fluorescence enhancement. By constructing a gradient ultrasonic field in a microcavity, the platform concentrates the functionalized microspheres in a central position, accompanied by an enhanced fluorescence signal with a specific release. In addition, the programmable frequency modulation can also modify the acoustic potential well and effectively promote non-equilibrium chemical reactions such as CHA (25 min). Compared with the conventional catalytic hairpin assembly (CHA), UECHA allows for direct and quantitative measurement of AD miRNAs down to 3.55 × 10-15 M in 1 μL samples. This visual analysis of ultra-trace biomarkers based on acoustic enrichment and promotion provides a new perspective for the rapid and highly sensitive clinical detection of Alzheimer's disease.

Emerging open-channel droplet arrays for biosensing

Open-channel droplet arrays have attracted much attention in the fields of biochemical analysis, biofluid monitoring, biomarker recognition and cell interactions, as they have advantages with regard to miniaturization, parallelization, high-throughput, simplicity and accessibility. Such droplet arrays not only improve the sensitivity and accuracy of a biosensor, but also do not require sophisticated equipment or tedious processes, showing great potential in next-generation miniaturized sensing platforms. This review summarizes typical examples of open-channel microdroplet arrays and focuses on diversified biosensing integrated with multiple signal-output approaches (fluorescence, colorimetric, surface-enhanced Raman scattering (SERS), electrochemical, etc.). The limitations and development prospects of open-channel droplet arrays in biosensing are also discussed with regard to the increasing demand for biosensors.

Emerging nanotechnology for Alzheimer's disease: From detection to treatment

Alzheimer's disease (AD), one of the most common chronic neurodegenerative diseases, is characterized by memory impairment, synaptic dysfunction, and character mutations. The pathological features of AD are Aβ accumulation, tau protein enrichment, oxidative stress, and immune inflammation. Since the pathogenesis of AD is complicated and ambiguous, it is still challenging to achieve early detection and timely treatment of AD. Due to the unique physical, electrical, magnetic, and optical properties of nanoparticles (NPs), nanotechnology has shown great potential for detecting and treating AD. This review provides an overview of the latest developments in AD detection via nanotechnology based on NPs with electrochemical sensing, optical sensing, and imaging techniques. Meanwhile, we highlight the important advances in nanotechnology-based AD treatment through targeting disease biomarkers, stem-cell therapy and immunotherapy. Furthermore, we summarize the current challenges and present a promising prospect for nanotechnology-based AD diagnosis and intervention.

Vertical Graphene-Based Printed Electrochemical Biosensor for Simultaneous Detection of Four Alzheimer's Disease Blood Biomarkers

Early detection and timely intervention play a vital role in the effective management of Alzheimer's disease. Currently, the diagnostic accuracy for Alzheimer's disease based on a single blood biomarker is relatively low, and the combined use of multiple blood biomarkers can greatly improve diagnostic accuracy. Herein, we report a printed electrochemical biosensor based on vertical graphene (VG) modified with gold nanoparticles (VG@nanoAu) for the simultaneous detection of four Alzheimer's disease blood biomarkers. The printed electrochemical electrode array was constructed by laser etching and inkjet printing. Then gold nanoparticles were modified onto the working electrode surface via electrodeposition to further improve the sensitivity of the sensor. In addition, the entire printed electrochemical sensing system incorporates an electrochemical micro-workstation and a smartphone. The customized electrochemical micro-workstation incorporates four electro-chemical control chips, enabling the sensor to simultaneously analyze four biomarkers. Consequently, the printed electrochemical sensing system exhibits excellent analytical performance due to the large surface area, biocompatibility, and good conductivity of VG@nanoAu. The detection limit of the sensing system for Aβ40, Aβ42, T-tau, and P-tau181 was 0.072, 0.089, 0.071, and 0.051 pg/mL, respectively, which meets the detection requirements of Alzheimer's disease blood biomarkers. The printed electrochemical sensing system also exhibits good specificity and stability. This work has great value and promising prospects for early Alzheimer's disease diagnosis using blood biomarkers.

Electrochemical Immunosensors Developed for Amyloid-Beta and Tau Proteins, Leading Biomarkers of Alzheimer's Disease

Alzheimer's disease (AD) is the most common neurological disease and a serious cause of dementia, which constitutes a threat to human health. The clinical evidence has found that extracellular amyloid-beta peptides (Aβ), phosphorylated tau (p-tau), and intracellular tau proteins, which are derived from the amyloid precursor protein (APP), are the leading biomarkers for accurate and early diagnosis of AD due to their central role in disease pathology, their correlation with disease progression, their diagnostic value, and their implications for therapeutic interventions. Their detection and monitoring contribute significantly to understanding AD and advancing clinical care. Available diagnostic techniques, including magnetic resonance imaging (MRI) and positron emission tomography (PET), are mainly used to validate AD diagnosis. However, these methods are expensive, yield results that are difficult to interpret, and have common side effects such as headaches, nausea, and vomiting. Therefore, researchers have focused on developing cost-effective, portable, and point-of-care alternative diagnostic devices to detect specific biomarkers in cerebrospinal fluid (CSF) and other biofluids. In this review, we summarized the recent progress in developing electrochemical immunosensors for detecting AD biomarkers (Aβ and p-tau protein) and their subtypes (AβO, Aβ_(1-40), Aβ_(1-42), t-tau, cleaved-tau (c-tau), p-tau₁₈₁, p-tau₂₃₁, p-tau₃₈₁, and p-tau₄₄₁). We also evaluated the key characteristics and electrochemical performance of developed immunosensing platforms, including signal interfaces, nanomaterials or other signal amplifiers, biofunctionalization methods, and even primary electrochemical sensing performances (i.e., sensitivity, linear detection range, the limit of detection (LOD), and clinical application).

Signal differentiation models for multiple microRNA detection: a critical review

MicroRNAs (miRNAs) are a class of small, single-stranded non-coding RNAs which have critical functions in various biological processes. Increasing evidence suggested that abnormal miRNA expression was closely related to many human diseases, and they are projected to be very promising biomarkers for non-invasive diagnosis. Multiplex detection of aberrant miRNAs has great advantages including improved detection efficiency and enhanced diagnostic precision. Traditional miRNA detection methods do not meet the requirements of high sensitivity or multiplexing. Some new techniques have opened novel paths to solve analytical challenges of multiple miRNA detection. Herein, we give a critical overview of the current multiplex strategies for the simultaneous detection of miRNAs from the perspective of two different signal differentiation models, including label differentiation and space differentiation. Meanwhile, recent advances of signal amplification strategies integrated into multiplex miRNA methods are also discussed. We hope this review provides the reader with future perspectives on multiplex miRNA strategies in biochemical research and clinical diagnostics.

Intelligent analysis of carbendazim in agricultural products based on a ZSHPC/MWCNT/SPE portable nanosensor combined with machine learning methods

A nano-ZnS-decorated hierarchically porous carbon (ZSHPC) was mixed with MWCNTs to obtain ZSHPC/MWCNT nanocomposites. Then, ZSHPC/MWCNTs were used to modify a screen-printed electrode, and a portable electrochemical detection system combined with machine learning methods was used to investigate carbendazim (CBZ) residues in rice and tea. The electrochemical performance of the constructed electrode showed that the electrode had good electrocatalytic ability, large effective surface area, strong stability and anti-interference ability. Support Vector Machine (SVM), Least Square Support Vector Machine (LS-SVM) and Back Propagation-Artificial Neural Network (BP-ANN) were used to establish the prediction model for CBZ residues in rice and tea, and the traditional linear regression was developed. The investigated results showed that the LS-SVM model had the best prediction performance and the lowest prediction error compared with the traditional linear regression, BP-ANN and SVM models. The R², RMSE, and MAE for the training set samples were 0.9969, 0.3605 and 0.2968, respectively. The R², RMSE, MAE and RPD for the prediction set samples were 0.9924, 0.6190, 0.5360 and 10.3097, respectively. The average recovery range of CBZ in tea and rice was 98.77-109.32% and that of RSD was 0.47-2.58%, indicating that the rapid analysis of CBZ pesticide residues in agricultural products based on a portable electrochemical detection system combined with machine learning was feasible.

An electrochemical aptasensor based on AuNRs/AuNWs for sensitive detection of apolipoprotein A-1 (ApoA1) from human serum

For early detection and diagnosis of cancer, it is essential to develop an electrochemical biosensor that is quick, accurate, and sensitive. Here, we use gold nanorod (AuNR) and gold nanowire (AuNW) nanocomposites (AuNR/AuNW/CS) as electrode modifiers on a glassy carbon electrode (GCE) to construct a sensitive label-free electrochemical aptasensor to detect ApoA1. The thiolated ApoA1-specific aptamers were immobilized onto the modified electrode surface through self-assembled monolayers. Electrochemical techniques, such as cyclic voltammetry (CV) and differential pulse voltammetry (DPV), were used to analyze the fabrication steps. The concentration of ApoA1 was measured with DPV on the aptasensor, with a linear range of 0.1 to 1000 pg mL^-1 and a detection limit of 0.04 pg mL^-1. When compared to results from ELISA tests (which have a detection limit of 80 pg mL^-1), the results achieved here were over 2000 times better. The aptasensor's performance was successfully evaluated using human serum spiked with ApoA1, suggesting that it has great potential for practical application. The electrochemical apatsensor additionally demonstrated outstanding selectivity responses and strong stability toward the target analyte.

Electrochemical immunosensor based on superwettable microdroplet array for detecting multiple Alzheimer's disease biomarkers

Alzheimer's disease (AD) is a neurodegenerative disease caused by neurons damage in the brain, and it poses a serious threat to human life and health. No efficient treatment is available, but early diagnosis, discovery, and intervention are still crucial, effective strategies. In this study, an electrochemical sensing platform based on a superwettable microdroplet array was developed to detect multiple AD biomarkers containing Aβ40, Aβ42, T-tau, and P-tau181 of blood. The platform integrated a superwettable substrate based on nanoAu-modified vertical graphene (VG@Au) into a working electrode, which was mainly used for droplet sample anchoring and electrochemical signal generation. In addition, an electrochemical micro-workstation was used for signals conditioning. This superwettable electrochemical sensing platform showed high sensitivity and a low detection limit due to its excellent characteristics such as large specific surface, remarkable electrical conductivity, and good biocompatibility. The detection limit for Aβ40, Aβ42, T-tau, and P-tau181 were 0.064, 0.012, 0.039, and 0.041 pg/ml, respectively. This study provides a promising method for the early diagnosis of AD.

Dual-emitting Iridium nanorods combining dual-regulating coreaction accelerator Ag nanoparticles for electrochemiluminescence ratio determination of amyloid-β oligomers

Iridium(III) complexes have been developed as eminent electrochemiluminescence (ECL) luminophores, but their current applications are only limited to anodic ECL emission because of weak cathodic ECL emission. This work explored poly(styrene-co-maleicanhydride) (PSMA) as functional reagent to modulate iridium(III) complexes to simultaneously emit bipolar ECL signals. The prepared iridium(III) nanorods (Ir NRs) were detected strong bipolar ECL emissions at +0.9 V and -2.0 V with N,N-diisopropylethylenediamine (DPEA) and persulfate (S₂O₈^2-) as coreactant, respectively. Meanwhile, Ag nanoparticles (Ag NPs) were developed as dual-regulating coreaction accelerator to boost the bipolar emissions of Ir NRs simultaneously. The dual-emitting Ir NRs coupled with dual-regulating coreaction accelerator Ag NPs facilitated the construction of mono-luminophore-based ECL ratio strategy for detecting amyloid-β oligomers (AβO). When the target AβO appeared, the Mg²⁺-dependent DNAzyme-powered biped walkers were unlocked to cleave single-stranded S1 immobilized on the surface of magnetic beads (MBs), resulting in the production of massive single-stranded ST. Then, the output ST cleaved hairpin H1 captured by Ir NRs modified electrode to produce numerous single strands, which could initiate the hybridization chain reaction (HCR) between Ag NPs-labeled H2 and Ag NPs-labeled H3 to introduce abundant Ag NPs onto the electrode surface. Due to the enhancement effect of Ag NPs on the bipolar ECL emissions from Ir NRs, the ECL ratio detection of AβO was achieved with the detection limit of 0.62 pM. The unique dual-emitting properties of Ir NRs coupled with dual-regulating effect of Ag NPs provided an interesting mono-luminophore-based ECL ratio sensing platform for biological analysis.

Electrochemical Quantitation of the Glycosylation Level of Serum Neurofilament Light Chain for the Diagnosis of Neurodegeneration: An Interface-Solution Dual-Path Amplification Strategy

Serum neurofilament light chain (NFL), a potential general biomarker for neurodegenerative diseases, is not specific enough to differentiate neurodegenerative diseases from other brain diseases such as cerebral thrombosis (CT). According to the importance of glycosylation in neurodegenerative pathogenesis, the NFL glycosylation level (oNFL/tNFL), defined as the ratio of glycosylated NFL (oNFL) to total NFL (tNFL), may be a more effective index. The major challenge in serum oNFL/tNFL detection is the ultra-low abundance of both NFL forms. In this paper, we achieved a convenient one-step electrochemical quantitation of oNFL/tNFL based on an interface-solution dual-path amplification strategy. Two amplified electrochemical signals─the reduction of Cu²⁺ from adsorbed porous nanoparticles on the sensor interface and the reduction of O₂ from horseradish peroxidase-catalyzed H₂O₂ disproportionation in solution─were adopted to quantify tNFL and oNFL, respectively. The electrochemical sensor displayed good sensitivity, selectivity, and reproducibility. The dynamic range is 1-25 pg mL^-1 for tNFL and 0.25-25 pg mL^-1 for oNFL, respectively. By analyzing the clinic serum samples, for the first time, our work provided the abundance of oNFL in human serum and revealed that the oNFL/tNFL is effective not only in differentiating three kinds of brain damage patients from healthy people but also in differentiating neurodegeneration from non-neurodegeneration CT patients. As a general biomarker, the oNFL/tNFL is more specific than NFL, which is hoped to be a new and valid indicator for the diagnosis, progression, prediction, and treatment evaluation of neurodegenerative diseases.

Portable Vertical Graphene@Au-Based Electrochemical Aptasensing Platform for Point-of-Care Testing of Tau Protein in the Blood

Alzheimer's disease (AD) is a long-term neurodegenerative disease that poses a serious threat to human life and health. It is very important to develop a portable quantitative device for AD diagnosis and personal healthcare. Herein, we develop a portable electrochemical sensing platform for the point-of-care detection of AD biomarkers in the blood. Such a portable platform integrates nanoAu-modified vertical graphene (VG@Au) into a working electrode, which can significantly improve sensitivity and reduce detection limit due to the large specific surface, excellent electrical conductivity, high stability, and good biocompatibility. The tau protein, as an important factor in the course of AD, is selected as a key AD biomarker. The results show that the linear range of this sensing platform is 0.1 pg/mL to 1 ng/mL, with a detection limit of 0.034 pg/mL (S/N = 3), indicating that this portable sensing platform meets the demand for the detection of the tau protein in the blood. This work offers great potential for AD diagnosis and personal healthcare.

Recent Advances of MXene-Based Electrochemical Immunosensors

Electrochemical immunosensors are the largest class of affinity biosensing devices with strong practicability. In recent years, MXenes have become hotspot materials of electrochemical biosensors for their excellent properties, including large specific surface area, good electrical conductivity, high hydrophilicity and rich functional groups. In this review, we firstly introduce the composition and structure of MXenes, as well as their properties relevant to the construction of biosensors. Then, we summarize the recent advances of MXenes-based electrochemical immunosensors, focusing on the roles of MXenes in various electrochemical immunosensors. Finally, we analyze current problems of MXenes-based electrochemical immunosensors and propose an outlook for this research field.

Superwettable Biosensor for Disease Biomarker Detection

Bioinspired superwettable materials have aroused wide interests in recent years for their promising application fields from service life to industry. As one kind of emerging application, the superwettable surfaces used to fabricate biosensors for the detection of disease biomarkers, especially tumor biomarkers, have been extensively studied. In this mini review, we briefly summarized the sensing strategy for disease biomarker detection based on superwettable biosensors, including fluorescence, electrochemistry, surface-enhanced Raman scattering, and visual assays. Finally, the challenges and direction for future development of superwettable biosensors are also discussed.